Search over 3,000 reports

    Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market 2027

    Transthyretin Amyloidosis (ATTR)  Competitive Landscape, Market Insights, Epidemiology and Market 2027
    Date: Mar, 2018
    Type: Pharmaceutical Industry Report
    Pages: 120
    Geography: Global
    Delivery Timeline: 24 hours
    SKU: DISR0019

    DelveInsight’s “Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027” Report provides an overview of the disease and market size of Transthyretin Amyloidosis for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report also covers the overview, treatment practice and Transthyretin Amyloidosis forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

    Transthyretin Amyloidosis (ATTR) Product Profiles & Analysis
    The drug chapter segment covers the complete analysis of marketed drugs, Phase III, Phase II, Phase 1 and Preclinical pipeline drugs. This division focuses on the recent breakthroughs 
    like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings.

    Epidemiology Insights
    The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Transthyretin Amyloidosis in the respective markets. The epidemiology data
    is presented with graphs and tables to provide a clear assessment of the landscape.

    Transthyretin Amyloidosis (ATTR) Market Outlook
    The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, the impact of emerging technology in the forecast period. The views from 
    the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Transthyretin Amyloidosis (ATTR) market.
     

    Emerging Therapies Analysis
    Transthyretin Amyloidosis treatment landscape is set to change by the imminent entry of major players such as Alnylam Pharmaceuticals, Corino Therapeutics, Sanofi Aventis and Ionis Pharmaceuticals, which are focusing on developing therapies that are expected to create a positive impact on the market of this disease. Out of these companies, Patisiran of Alnylam Pharmaceuticals- Sanofi is expected to enter the market in June 2018 as a standard treatment of TTR-FAP, followed by the launch of Inotersen by Ionis Pharmaceuticals Inc. Apart from these, CRX-1008 of Corino Therapeutics Inc. is expected to enter market by 2023, however may face tough competition to grab market share, due to the presence of drugs already approved.

     

    It comprehensively includes:

    • The descriptive overview of the Transthyretin Amyloidosis, explaining its pathophysiology, diagnostic approaches and treatment algorithm
    • An insight into the epidemiology of the disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
    • A comprehensive account of both the current and emerging therapies, assessing the impact of new therapies on the current treatment landscape
    • The detailed global historical and forecasted Transthyretin Amyloidosis market including the drug outreach in 7 MM
    • It will help in developing business strategies by understanding trends shaping and driving the global Transthyretin Amyloidosis market

    Key Strengths

    1. 10 Years Forecast (2018-2027)
    2. 7MM Coverage
    3. Epidemiology Subtype Segmentation
    4. Key Cross Competition
    5. Market Size by Therapies
    6. Complete Pipeline Portfolio

    Key Assessments

    1. Pipeline Product Profiles
    2. Key Products and Key Players
    3. Market Drivers and Barriers

    Reasons to buy:

    • The report will help in developing business strategies by understanding trends shaping and driving the Transthyretin Amyloidosis market.
    • To understand the future market competition in the Transthyretin Amyloidosis market and Insight reviews of the key market drivers and barriers.
    • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
    • In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

     

     

     

     

     

     

     

     

    1.            Report Introduction

    2.            Transthyretin Amyloidosis Market Overview at a Glance

    2.1.         Market Share (%) Distribution of Transthyretin Amyloidosis in 2016

    2.2.         Market Share (%) Distribution of Transthyretin Amyloidosis in 2027

    3.            Disease Background and Overview: Transthyretin-related amyloidosis

    3.1.         Introduction

    3.2.         Clinical aspects of ATTR

    3.3.         Types of Transthyretin Amyloidosis

    3.4.         Causes

    3.5.         Symptoms

    3.6.         Pathogenesis

    3.7.         Diagnosis

    3.7.1.     Tools for evaluating TTR-FAP progression

    4.            Epidemiology and Patient Population

    4.1.         Key Findings

    4.2.         Population and Forecast Parameters

    4.3.         7MM Diagnosed Prevalent Population of ATTR

    4.4.         Type-specific Diagnosed Prevalent Population of ATTR in 7MM

    5.            Epidemiology by Country

    5.1.         United States

    5.1.1.     Diagnosed Prevalent Population of ATTR in the United States

    5.1.2.     Type-specific Diagnosed Prevalent Population of hATTR in the United States

    5.1.3.     Treatable cases of Transthyretin Amyloidosis in the United States

    5.2.         European Union Five

    5.2.1.     United Kingdom

    5.2.1.1. Diagnosed Prevalent Population of ATTR in the United Kingdom

    5.2.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom

    5.2.1.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom

    5.2.2.     Germany

    5.2.2.1. Diagnosed Prevalent Population of ATTR in Germany

    5.2.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany

    5.2.2.3. Treatable cases of Transthyretin Amyloidosis in Germany

    5.2.3.     Italy

    5.2.3.1. Diagnosed Prevalent Population of ATTR in Italy

    5.2.3.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy

    5.2.3.3. Treatable cases of Transthyretin Amyloidosis in Italy

    5.2.4.     Spain

    5.2.4.1. Diagnosed Prevalent Population of ATTR in Spain

    5.2.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain

    5.2.4.3. Treatable cases of Transthyretin Amyloidosis in Spain

    5.2.5.     France

    5.2.5.1. Diagnosed Prevalent Population of ATTR in France

    5.2.5.2. Type-specific Diagnosed Prevalent Population of hATTR in France

    5.2.5.3. Treatable cases of Transthyretin Amyloidosis in France

    5.3.         Japan

    5.3.1.     Diagnosed Prevalent Population of ATTR in Japan

    5.3.2.     Type-specific Diagnosed Prevalent Population of hATTR in Japan

    5.3.3.     Treatable cases of Transthyretin Amyloidosis in Japan

    6.            7MM Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome

    6.1.         Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United States

    6.2.         Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United Kingdom

    6.3.         Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany

    6.4.         Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy

    6.5.         Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France

    6.6.         Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan

    7.            Current Treatment and Medical Practices

    7.1.         Treatment Guidelines

    7.1.1.     First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

    8.            Unmet Needs

    9.            Marketed Drugs

    9.1.         Vyndaqel: Pfizer Inc.

    9.1.1.     Drug Description

    9.1.2.     Mechanism of Action

    9.1.3.     Regulatory Milestones

    9.1.4.     Advantages & Disadvantages

    9.1.5.     Safety and Efficacy

    9.1.6.     Ongoing trial description, 2017

    9.1.7.     Product Profile

    10.          Therapeutics under Development by Companies

    10.1.      Key Cross Competition

    10.2.      Clinical Products (Phase III to Phase I]

    10.2.1.   Patisiran: Alnylam Pharmaceuticals

    10.2.1.1.               Regulatory Milestones

    10.2.1.2.               Other development activities

    10.2.1.3.               Clinical Development

    10.2.1.4.               Clinical Trials Information

    10.2.1.5.               Safety and Efficacy

    10.2.1.6.               Product Profile

    10.2.2.   Inotersen: Ionis Pharmaceuticals Inc.

    10.2.2.1.               Regulatory Milestones

    10.2.2.2.               Other development activities

    10.2.2.3.               Clinical Development

    10.2.2.4.               Clinical Trials Information

    10.2.2.5.               Safety and Efficacy

    10.2.2.6.               Product Profile

    10.2.3.   CRX-1008: Corino Therapeutics Inc.

    10.2.3.1.               Regulatory Milestones

    10.2.3.2.               Other development activities

    10.2.3.3.               Clinical Development

    10.2.3.4.               Clinical Trials Information

    10.2.3.5.               Safety and Efficacy

    10.2.3.6.               Product Profile

    To be continued in the report...

    10.3.      Non-Clinical Products

    10.3.1.   NPT189: Proclara Bioscience

    10.3.1.1.               Drug Description

    10.3.1.2.               Pre-Clinical results

    10.3.1.3.               Other development activities

    10.3.1.4.               Product Profile

    10.3.2.   LUNAR-101: Arcturus Therapeutics

    10.3.2.1.               Drug Description

    10.3.2.2.               Pre-Clinical results

    10.3.2.3.               Other development activities

    10.3.2.4.               Product Profile

    To be continued in the report…

    11.          Therapeutic Assessment

    11.1.      Assessment by Monotherapy Products

    11.2.      Assessment by Combination Products

    11.3.      Assessment by Route of Administration

    11.4.      Assessment by Stage and Route

    11.5.      Assessment by Molecule Type

    11.6.      Assessment by Stage and Molecule Type

    11.7.      Assessment by Domain

    11.8.      Assessment by Stage and Domain

    12.          Transthyretin Amyloidosis: Market Analysis

    12.1.      Transthyretin Amyloidosis: 7 Major Market Outlook

    12.1.1.   Market size of Transthyretin Amyloidosis in 7MM

    12.1.2.   Therapy Based Market size of Transthyretin Amyloidosis in 7MM

    13.          Market Outlook by Country

    13.1.      Transthyretin Amyloidosis: United States Market Analysis

    13.1.1.   United States Market size

    13.1.2.   Therapy-Based Market Size of Transthyretin Amyloidosis

    13.2.      Transthyretin Amyloidosis: EU5 Market Analysis

    13.2.1.   Germany

    13.2.1.1.               Germany Market size

    13.2.1.2.               Therapy Based Market Size of Transthyretin Amyloidosis

    13.2.2.   France

    13.2.2.1.               France Market size

    13.2.2.2.               Therapy Based Market Size of Transthyretin Amyloidosis

    13.2.3.   United Kingdom

    13.2.3.1.               United Kingdom Market size

    13.2.3.2.               Therapy Based Market Size of Transthyretin Amyloidosis

    13.2.4.   Spain

    13.2.4.1.               Spain Market size

    13.2.4.2.               Therapy Based Market Size of Transthyretin Amyloidosis

    13.2.5.   Italy

    13.2.5.1.               Italy Market size

    13.2.5.2.               Therapy Based Market Size of Transthyretin Amyloidosis

    13.3.      Transthyretin Amyloidosis: Japan Market Analysis

    13.3.1.   Japan Market size

    13.3.2.   Therapy Based Market Size of Transthyretin Amyloidosis

    14.          Market Drivers

    15.          Market Barriers

    16.          Appendix

    17.          Report Methodology

    17.1.      Sources Used

    18.          DelveInsight Capabilities

    19.          Disclaimer

    20.          About DelveInsight

    Table 1                  Diagnosed Prevalent Population of ATTR in 7MM (2015-2027)

    Table 2                  7MM-Type Specific Diagnosed Prevalent Population of ATTR (2015-2027)

    Table 3                  Diagnosed Prevalent Population of ATTR in US (2015-2027)

    Table 4                  Type-specific Diagnosed Prevalent Population of ATTR in US (2015-2027)

    Table 5                  Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)

    Table 6                  Diagnosed Prevalent Population of ATTR in UK (2015-2027)

    Table 7                  Type-specific Diagnosed Prevalent Population of ATTR in UK (2015-2027)

    Table 8                 Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)

    Table 9                  Diagnosed Prevalent Population of ATTR in Germany (2015-2027)

    Table 10               Type-specific Diagnosed Prevalent Population of ATTR in Germany (2015-2027)

    Table 11               Treatable cases of Transthyretin Amyloidosis (ATTR) in Germany (2015-2027)

    Table 12               Diagnosed Prevalent Population of ATTR in Italy (2015-2027)

    Table 13               Type-specific Diagnosed Prevalent Population of ATTR in Italy (2015-2027)

    Table 14               Treatable cases of Transthyretin Amyloidosis (ATTR) in Italy (2015-2027)

    Table 15               Diagnosed Prevalent Population of ATTR in Spain (2015-2027)

    Table 16               Type-specific Diagnosed Prevalent Population of ATTR in Spain (2015-2027)

    Table 17               Treatable cases of Transthyretin Amyloidosis (ATTR) in Spain (2015-2027)

    Table 18               Diagnosed Prevalent Population of ATTR in France (2015-2027)

    Table 19               Type-specific Diagnosed Prevalent Population of ATTR in France (2015-2027)

    Table 20               Treatable cases of Transthyretin Amyloidosis (ATTR) in France (2015-2027)

    Table 21               Diagnosed Prevalent Population of ATTR in Japan (2015-2027)

    Table 22               Type-Specific Diagnosed Prevalent Population of ATTR in Japan (2015-2027)

    Table 23               Treatable cases of Transthyretin Amyloidosis (ATTR) in Japan (2015-2027)

    Table 24               7MM Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome (2015-2027)

    Table 25               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in US (2015-2027)

    Table 26               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in UK (2015-2027)

    Table 27               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2015-2027)

    Table 28               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2015-2027)

    Table 29               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2015-2027)

    Table 30               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2015-2027)

    Table 31               Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2015-2027)

    Table 32               Tafamidis, Clinical Trial Description, 2018

    Table 33               Patisiran, Clinical Trial Description, 2018

    Table 34               Inotersen , Clinical Trial Description, 2018

    Table 35               CRX-1008, Clinical Trial Description, 2018

    Table 36               Clinical Stage Products, 2018

    Table 37               Pre-Clinical Stage Products, 2018

    Table 38               Assessment by Monotherapy Products, 2018

    Table 39               Assessment by Combination Products, 2018

    Table 40               Assessment by Route Of Administration, 2018

    Table 41               Assessment by Stage and Route Of Administration, 2018

    Table 42               Assessment by Molecule Type, 2018

    Table 43               Assessment by Stage and Molecule Type, 2018

    Table 44               Assessment by Stage of development and Domain, 2018

    Table 45               7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 46               7 Major Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 47               7 Major Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 48               Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)

    Table 49               Type Specific Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)

    Table 50               Therapy-Wise Market Size of Transthyretin Amyloidosis  in the United States, USD Millions (2015 -2027)

    Table 51               United States Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 52               Market Size of Transthyretin Amyloidosis  in the Germany, USD Millions (2015 -2027)

    Table 53               Type Specific Market Size of Transthyretin Amyloidosis in Germany, USD Millions (2015 -2027)

    Table 54               Therapy-Wise Market Size of Transthyretin Amyloidosis  in Germany, USD Millions (2015 -2027)

    Table 55               Germany Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 56               Market Size of Transthyretin Amyloidosis  in France, USD Millions (2015 -2027)

    Table 57               Type Specific Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)

    Table 58               Therapy-Wise Market Size of Transthyretin Amyloidosis  in France, USD Millions (2015 -2027)

    Table 59               France Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 60               Market Size of Transthyretin Amyloidosis  in the United Kingdom, USD Millions (2015 -2027)

    Table 61               Type Specific Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)

    Table 62               Therapy-Wise Market Size of Transthyretin Amyloidosis  in the United Kingdom, USD Millions (2015 -2027)

    Table 63               United Kingdom Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 64               Market Size of Transthyretin Amyloidosis  in Spain, USD Millions (2015 -2027)

    Table 65               Type Specific Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)

    Table 66               Therapy-Wise Market Size of Transthyretin Amyloidosis  in Spain, USD Millions (2015 -2027)

    Table 67               Spain Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 68               Market Size of Transthyretin Amyloidosis  in Italy, USD Millions (2015 -2027)

    Table 69               Type Specific Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)

    Table 70               Therapy-Wise Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)

    Table 71               Italy Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Table 72               Market Size of Transthyretin Amyloidosis  in Japan, USD Millions (2015 -2027)

    Table 73               Type Specific Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)

    Table 74               Therapy-Wise Market Size of Transthyretin Amyloidosis  in Japan, USD Millions (2015 -2027)

    Table 75               Japan Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 1                Diagnosed Prevalent Population of ATTR in 7MM (2015-2027)

    Figure 2                7MM-Type Specific Diagnosed Prevalent Population of ATTR (2015-2027)

    Figure 3                Diagnosed Prevalent Population of ATTR in US (2015-2027)

    Figure 4                Type-specific Diagnosed Prevalent Population of ATTR in US (2015-2027)

    Figure 5                Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)

    Figure 6                Diagnosed Prevalent Population of ATTR in UK (2015-2027)

    Figure 7                Type-specific Diagnosed Prevalent Population of ATTR in UK (2015-2027)

    Figure 8                Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)

    Figure 9                Diagnosed Prevalent Population of ATTR in Germany (2015-2027)

    Figure 10              Type-specific Diagnosed Prevalent Population of ATTR in Germany (2015-2027)

    Figure 11              Treatable cases of Transthyretin Amyloidosis (ATTR) in Germany (2015-2027)

    Figure 12              Diagnosed Prevalent Population of ATTR in Italy (2015-2027)

    Figure 13              Type-specific Diagnosed Prevalent Population of ATTR in Italy (2015-2027)

    Figure 14              Treatable cases of Transthyretin Amyloidosis (ATTR) in Italy (2015-2027)

    Figure 15              Diagnosed Prevalent Population of ATTR in Spain (2015-2027)

    Figure 16              Type-specific Diagnosed Prevalent Population of ATTR in Spain (2015-2027)

    Figure 17              Treatable cases of Transthyretin Amyloidosis (ATTR) in Spain (2015-2027)

    Figure 18              Diagnosed Prevalent Population of ATTR in France (2015-2027)

    Figure 19              Type-specific Diagnosed Prevalent Population of ATTR in France (2015-2027)

    Figure 20              Treatable cases of Transthyretin Amyloidosis (ATTR) in France (2015-2027)

    Figure 21              Diagnosed Prevalent Population of ATTR in Japan (2015-2027)

    Figure 22              Type-Specific Diagnosed Prevalent Population of ATTR in Japan (2015-2027)

    Figure 23              Treatable cases of Transthyretin Amyloidosis (ATTR) in Japan (2015-2027)

    Figure 24              7MM Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome (2015-2027)

    Figure 25              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in US (2015-2027)

    Figure 26              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in UK (2015-2027)

    Figure 27              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2015-2027)

    Figure 28              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2015-2027)

    Figure 29              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2015-2027)

    Figure 30              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2015-2027)

    Figure 31              Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2015-2027)

    Figure 32              Tafamidis, Clinical Trial Description, 2018

    Figure 33              Patisiran, Clinical Trial Description, 2018

    Figure 34              Inotersen , Clinical Trial Description, 2018

    Figure 35              CRX-1008, Clinical Trial Description, 2018

    Figure 36              Clinical Stage Products, 2018

    Figure 37              Pre-Clinical Stage Products, 2018

    Figure 38              Assessment by Monotherapy Products, 2018

    Figure 39              Assessment by Combination Products, 2018

    Figure 40              Assessment by Route Of Administration, 2018

    Figure 41              Assessment by Stage and Route Of Administration, 2018

    Figure 42              Assessment by Molecule Type, 2018

    Figure 43              Assessment by Stage and Molecule Type, 2018

    Figure 44              Assessment by Stage of development and Domain, 2018

    Figure 45              7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 46              7 Major Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 47              7 Major Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 48              Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)

    Figure 49              Type Specific Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)

    Figure 50              Therapy-Wise Market Size of Transthyretin Amyloidosis  in the United States, USD Millions (2015 -2027)

    Figure 51              United States Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 52              Market Size of Transthyretin Amyloidosis  in the Germany, USD Millions (2015 -2027)

    Figure 53              Type Specific Market Size of Transthyretin Amyloidosis in Germany, USD Millions (2015 -2027)

    Figure 54              Therapy-Wise Market Size of Transthyretin Amyloidosis  in Germany, USD Millions (2015 -2027)

    Figure 55              Germany Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 56              Market Size of Transthyretin Amyloidosis  in France, USD Millions (2015 -2027)

    Figure 57              Type Specific Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)

    Figure 58              Therapy-Wise Market Size of Transthyretin Amyloidosis  in France, USD Millions (2015 -2027)

    Figure 59              France Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 60              Market Size of Transthyretin Amyloidosis  in the United Kingdom, USD Millions (2015 -2027)

    Figure 61              Type Specific Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)

    Figure 62              Therapy-Wise Market Size of Transthyretin Amyloidosis  in the United Kingdom, USD Millions (2015 -2027)

    Figure 63              United Kingdom Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 64              Market Size of Transthyretin Amyloidosis  in Spain, USD Millions (2015 -2027)

    Figure 65              Type Specific Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)

    Figure 66              Therapy-Wise Market Size of Transthyretin Amyloidosis  in Spain, USD Millions (2015 -2027)

    Figure 67              Spain Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 68              Market Size of Transthyretin Amyloidosis  in Italy, USD Millions (2015 -2027)

    Figure 69              Type Specific Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)

    Figure 70              Therapy-Wise Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)

    Figure 71              Italy Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Figure 72              Market Size of Transthyretin Amyloidosis  in Japan, USD Millions (2015 -2027)

    Figure 73              Type Specific Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)

    Figure 74              Therapy-Wise Market Size of Transthyretin Amyloidosis  in Japan, USD Millions (2015 -2027)

    Figure 75              Japan Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

    Pfizer
    Alnylam Pharmaceuticals
    Ionis Pharmaceuticals Inc.
    Corino Therapeutics Inc.
    Proclara Bioscience
    Arcturus Therapeutics
    • Single User
      ()
      $7,500.00
    • Site License
      (30% Off)
      $15,000.00
    • Global License
      (40% Off)
      $22,500.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap